Results 251 to 260 of about 154,826 (359)

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience. [PDF]

Blood Cancer J
Moreau P, Hulin C, Talbot A, Demarquette H, Caillot L, Chalopin T, Bobin A, Manier S, Leleu X, Karlin L, Caillot D, Sonntag C, Feugier P, Roussel M, Gounot R, Macro M, Mohty M, Garderet L, Tiab M, Orsini-Piocelle F, Vincent L, Meuleman N, Fontan J, Montes L, Vekemans MC, Escoffre-Barbe M, Eveillard JR, Schiano de Colella JM, Lambert J, Mary JY, Fermand JP, Arnulf B, Corre J, Avet-Loiseau H, Facon T, Harousseau JL, Touzeau C, Perrot A.   +37 more
europepmc   +1 more source

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma

, 2019
Karen Sweiss, Gregory S. Calip, Jeremy J. Johnson, Damiano Rondelli, Pritesh Patel   +4 more
openalex   +2 more sources

Late infections after high-dose therapy and autologous stem cell transplantation for lymphoma: A Danish population-based study. [PDF]

Br J Haematol
Severinsen FT, Simonsen MR, Futtrup Maksten E, Jakobsen LH, Jensen RK, Søgaard KK, Jensen P, Brown PN, Mészáros Jørgensen J, Larsen TS, Poulsen CB, El-Galaly TC.   +11 more
europepmc   +1 more source

Phase 1/2 Study of Crizotinib in Children With Relapsed/Refractory ALK‐Positive Anaplastic Large Cell Lymphoma or Neuroblastoma in Japan

Cancer Science, EarlyView.
The safety and antitumor activity of crizotinib at a dose of 165 mg/m2 BID were evaluated in 16 patients with ALK‐positive ALCL in Japan. The most common grade 3 or 4 adverse event was neutropenia. The steady‐state Cmax and AUCtau of crizotinib at 165 mg/m2 BID were higher than expected. The objective response rate was 72.7% (90% CI, 43.6%–92.1%) among
Tetsuya Mori, Akiko Kada, Tomoo Osumi, Daisuke Tomizawa, Yuhki Koga, Reiji Fukano, Kengo Takeuchi, Ukihide Tateishi, Osamu Miyazaki, Ryuta Asada, Akiko M. Saito, Kei Fukuhara, Masahiro Sekimizu   +12 more
wiley   +1 more source

Targeting the Spleen as an Alternative Site for Hematopoiesis [PDF]

, 2019
Lim, Hong, O'Neill, Helen C, Short, Christie, Tan, Jonathan Kah Huat   +3 more
core   +1 more source

Position statement from the British Society of Blood and Marrow Transplantation and Cellular Therapy on insertional oncogenesis in gene‐engineered advanced cell therapy products for treatment of haematological disorders

British Journal of Haematology, EarlyView.
S. Ghorashian, R. Sanderson, J. Lee, A. Black, M. A. O'Reilly, D. I. Marks, J. Snowden, D. Richardson, E. Olavarria   +8 more
wiley   +1 more source

Expression of the CXCR4 S338X Variant Improves Anti‐Leukemia Efficacy of Anti‐CD19 CAR‐T Cells

Cancer Science, EarlyView.
Under normal conditions, CXCL12 stimulation induces CXCR4 degradation. In contrast, CAR19‐T cells expressing the CXCR4 S338X variant maintain receptor stability and sustain ERK and AKT signaling, which supports T‐cell effector function, migration, and survival. Therefore, the enhanced anti‐leukemic activity is conferred by CXCR4 S338X expression in CAR‐
Yushu Mao, Xiaodan Wang, Chun‐Hui Jin, Zhifeng Wei, Qinghao Ding, Ke‐Ke Zhang, Bo‐Wen Dong, Kai‐Wen Zheng, Yufei Hou, Tao Zhang, Wen‐Jie Zhao, Zheng Hu, Yong‐Guang Yang   +12 more
wiley   +1 more source

Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study. [PDF]

Adv Hematol
Filonenko K, Stepanishyna Y, Shokun N, Martynchyk A, Kushchevyi Y, Kriachok I, Zaucha JM.   +6 more
europepmc   +1 more source

Ethical and Regulatory Considerations in the Clinical Translation of Pluripotent Stem Cell‐Derived NK Cell Therapies

Cell Proliferation, EarlyView.
Advancements in the generation of human pluripotent stem cell‐derived natural killer (PSC‐NK) cells have attracted considerable attention within the biomedical research community, offering a promising off‐the‐shelf technique for universal immune therapy.
Qianwen Chen, Jianwei Lv, Xinwei Xie, Hanlin Zhu, Zhenyu Xiao, Yaojin Peng   +5 more
wiley   +1 more source